New combo attack for tough leukemia: CAR-T cells then transplant

NCT ID NCT07342244

Not yet recruiting Disease control Sponsor: Donghua Zhang Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a two-step treatment for people with acute myeloid leukemia (AML) that has come back or not responded to standard chemo. First, patients receive CLL1 CAR-T cells (engineered immune cells that target leukemia). Then they get a stem cell transplant from a donor. The goal is to see if this approach is safe and can help control the disease. Only 18 adults aged 18-75 will take part, and the study has not started recruiting yet.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CLL1 CAR-T cells followed by a donor stem cell transplant
What this could lead to: If it works, this could offer a new treatment path for people with hard-to-treat AML who have few options left.
What could go wrong: This is a very early, small trial (18 people) with no phase assigned. The combination therapy carries serious risks, including severe immune reactions and transplant complications. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML AML (ACUTE MYELOID LEUKEMIA)

Contacts and locations

Locations

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

Wuhan, Hubei, 448000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.